Active	Status	Sponsor type	Region	Phase	Filter
11 Active 3 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Piperno-Neumann, Sophie
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Recruiting	2/3	420	Europe, Canada, US, RoW	IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome	IDEAYA Biosciences	Metastatic Uveal Melanoma	01/27	01/28
SARCOME13, NCT03643133 / 2017-001165-24: Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients	Active, not recruiting	2	60	Europe	Mifamurtide, MEPACT, EI or M-API regimen depending on patient age	UNICANCER	Osteosarcoma	03/25	10/33
REGOBONE, NCT02389244 / 2013-003910-42: A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas Data from REGOBONE trial for relapsed advanced or metastatic chordoma at ESMO 2021 Jul 2021 - Jul 2021: Data from REGOBONE trial for relapsed advanced or metastatic chordoma at ESMO 2021	Active, not recruiting	2	163	Europe	Regorafenib, Stivarga, Placebo, Placebo tablet	UNICANCER	Ewing Sarcomas, Chondrosarcomas, Osteosarcomas, Chondroma, CIC-Rearranged Sarcoma	10/24	06/25
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma	Recruiting	2	82	Europe, Canada, US, RoW	Darovasertib, IDE196, LXS196	IDEAYA Biosciences	Uveal Melanoma	01/26	01/29
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer	Recruiting	2	105	Europe, Japan, US, RoW	Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide	Eli Lilly and Company	Neoplasms, Child, Adolescent	05/27	05/27
REGOMAIN, NCT04698785: Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients	Recruiting	2	36	Europe	Treatment by regorafenib and best supportive care, Experimental arm	Centre Leon Berard	Bone Sarcoma, Osteosarcoma	07/26	07/26
COTESARC, NCT04216953: MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma	Active, not recruiting	1/2	320	Europe	Cobimetinib, GDC-0973, Atezolizumab, RO5541267	Centre Leon Berard	Sarcoma,Soft Tissue	02/26	02/27
NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma	Terminated	1	76	Europe, US	FHD-286	Foghorn Therapeutics Inc.	Metastatic Uveal Melanoma	11/23	11/23
REGOSTA, NCT04055220 / 2018-004045-16: Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas	Recruiting	N/A	168	Europe	Treatment by Regorafenib, Stivarga, Treatment by Placebo, Standard of care	Centre Leon Berard	Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Angiosarcoma	10/26	10/26
SALOME, NCT04424719: Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse	Recruiting	N/A	700	Europe	Blood test, MRI in routine	Institut Curie	Uveal Melanoma	07/35	07/35
OPTISARC, NCT05272358: Economic Evaluation of Sarcoma Patients Management in France	Recruiting	N/A	2431	Europe	NETSARC network	Centre Leon Berard, École nationale supérieure des Mines Saint-Etienne France, Rennes University Hospital, Assistance Publique - Hôpitaux de Paris	Sarcoma	06/22	02/24